With some 45-60 new curative or durable therapies expected to hit the market by 2030, a key challenge facing the U.S. health system concerns how payers and drugmakers can collaborate to ensure broad access to those treatments, according to a blog post by the National Pharmaceutical Council.
“Paying for Cures,” a one-day event hosted Feb. 12 in Washington, focused on this issue with more than 250 participants, according to the blog post.
“Most of these treatments are gene therapies and immunotherapies targeted to rare, or ultra-rare, diseases for which there are no existing or very limited treatment options,” the blog post states. “For patients, these new types of treatments could represent a positive, dramatic shift in their daily lives.”
To read the full blog post on NPC’s website, click here.